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ABSTRACT (250 out of 250 words maximum)
Renal transplantation has transformed the life of patients with end-stage renal disease and other chronic kidney disorders by returning endogenous kidney function and enabling patients to cease dialysis. Several clinical indicators of graft outcome and long-term function have been established. Whilst rising creatinine levels and graft biopsy can be used to determine graft loss, identifying early predictors of graft function will not only improve our ability to predict longterm graft outcome but importantly provide a window of opportunity to therapeutically intervene to preserve graft function before graft failure has occurred. Since understanding the importance of matching genetic variation at the HLA region between donors and recipients and translating this into clinical practise to improve transplant outcome, much focus has been placed on trying to identify additional genetic predictors of transplant outcome/function. This review will focus on how candidate gene studies have identified variants within immunosuppression, immune response, fibrotic pathways and specific ethnic groups which correlate with graft outcome. We will also discuss the challenges faced by candidate gene studies, such as differences in donor and recipient selection criteria and use of small datasets, which have led to many genes failing to be consistently associated with transplant outcome. This review will also look at how recent advances in our understanding of and ability to screen the genome are starting to provide new insights into the mechanisms behind long-term graft loss and with it the opportunity to target these pathways therapeutically to ultimately increase graft lifespan and the associated benefits to patients. (4) . Whilst kidney biopsy and creatinine levels can determine graft failure, usually this is after substantial graft damage has occurred.
OVERVIEW (6500 words including
Due to the importance of providing equity of access to kidney transplants across different ethnic and social-economical groups and with waiting lists outstripping organ supply, it is not always possible to match purely on the best clinical indicators of long-term graft survival. It is also important to bear in mind that whilst clinical features provide indicators of transplant survival and long-term function, they are not definitive predictors of transplant longevity. One key feature of transplantation is that the donor and recipient, except between identical twins, differ in their genetic makeup. Utilisation of HLA matching has enabled transplantation to become one of the first fields to translate genetic information into improved graft outcome (3).
The use of genetic markers to predict disease outcome in common diseases has however been questioned as whilst genetic factors can predict disease outcome as well as clinical features, when added to well-established clinical predictors in common autoimmune and metabolic diseases they do not improve disease prediction (5, 6) . In transplantation where we do not have good clinical predictors of long-term graft survival/function, identifying genetic predictors of graft dysfunction could provide a window of opportunity to intervene therapeutically to prevent organ loss early on extending the benefits to patients of having a functioning graft.
The next section of this review is going to focus on the role of HLA mismatching in transplant outcome and the use of candidate gene studies to search for additional genetic predictors of graft outcome including variants involved in immunosuppressant metabolism, immune response, fibrosis and factors that contribute to transplant loss in different ethnicities (see Figure 1 ).
HLA Matching -The Original Genetic Predictor of Transplant Outcome
HLA antibodies represent a significant risk factor for hyper-acute rejection and can contribute to chronic rejection (3, 7). The HLA region encodes numerous molecules involved in presentation of exogenous and endogenous antigens for recognition by the immune system (8).
The immune system determines if antigens presented are self, triggering no response, or nonself, causing an immune response to be triggered. If the donor organ encodes different HLA molecules to those recognised by the recipient's immune system, when encountered by the immune system alloantibodies against the donor organ will be generated. Understanding that matching donors and recipients for HLA-DRB1, HLA-A and HLA-B would lead to reduced alloantibody production and improved transplant outcome is a keystone of most clinical transplant protocols.
HLA typing was initially undertaken looking at broad level (first field) matching between donors and recipients, based on HLA categorisation due to overarching structural similarities.
Whilst it was well established that zero HLA mismatches have the highest success rate, other non-matched HLA donor-recipient pairings also did well (7) . Split HLA specificities (second field) can further sub-divide the broad level typing by assigning the exact amino acid content at each broad HLA type. Both broad and split HLA typing give all mismatches the same weighting but does not reflect how each molecule presents antigens or how antibodies bind.
This led to development of the HLAMatchmaker algorithm which rather than viewing HLA molecules as whole molecules it views them as a series of short linear sequences (triplets) of polymorphic amino acid residues in antibody-accessible positions (9) (10) (11) . HLAMatchmaker assumes strings of amino acid form epitopes against which antibodies are created and patients cannot make antibodies against epitopes expressed by their own HLA molecules (12, 13) .
Revision to the original HLAMatchmaker was undertaken to take into account the three dimensional structure of HLA molecules with triplets expanded to include eplets, derived of longer discontinuous sequences of amino acids which form part of a given epitope (13) . This algorithm was particularly useful in interpreting sera antibody reactivity patterns against HLA panels in highly sensitized patients to determine donors with acceptable mismatches and has been incorporated into Eurotransplant's clinical protocol for highly sensitised patients, resulting in shorter waiting times for donor kidneys and graft survival rates comparable to those seen in non-sensitized patients (14-18).
There is debate, however, over whether using split HLA matching or HLAMatchmaker provides improvements over broad HLA matching in clinical practise. Kidney transplant outcome data reported to UNOS and Eurotransplant registries, suggested HLA matching of amino acid triplets improved graft survival compared to serologically define broad level HLA typing (19). However, it was suggested any benefit of triplet matching may be due to is controlled by presence of the 6986A>G (rs776746) SNP in intron 3. Whilst those with the CYP3A5 AA or AG genotype (also known as CYP3A5*1/*1 or CYP3A5*1/*3, respectively) express functional CYP3A5, CYP3A5 GG homozygous carriers (CYP3A5*3/*3) do not express functional CYP3A5. CYP3A5 non-expressers require less tacrolimus to reach target drug concentrations, compared to CYP3A5 expressers and whilst rejection occurred earlier in CYP3A5 expressors (7 days vs 14 days, p=0.005), no difference in biopsy confirmed acute rejection was seen (34). A randomized controlled trial comparing tacrolimus dosing using CYP3A5 genotype vs standard dosing showed target tacrolimus concentrations were reached quicker within the genotype-based group, however there were no differences in clinical outcome between groups, suggesting clinical utility of CYP3A5 genotype may be limited to reducing initial drug overexposure (35).
Variation in both CYP3A4 and ABCB1, encoding p-glycoprotein efflux pump transporter which transports drug metabolites out of the intestine, liver and kidneys, have also been extensively screened (30, 31). Unlike CYP3A5, no variants in CYP3A4 or ABCB1 cause total loss of function. The CYP3A4 -392A-G SNP (rs2740754), present within nifedipine-specific element (NFSE) within the 5' promoter region, has been extensively studied. Functional analysis of the -392 G allele (also referred to as CYP3A4*1B) showed increased CYP3A4 transcriptional activity, although these results are controversial (30, 31). More recent investigation of the CYP3A4 15389C-T (rs35599367) SNP in intron 6, showed the TT or CT genotypes (also known as CYP3A4*22/*22 and CYP3A4*1/*22 genotypes, respectively) was associated with lower CYP3A4 mRNA and protein expression in the liver compared to the CC genotype (CYP3A4*1/*1), and was proposed to impact on CYP3A4 function and in turn tacrolimus clearance (36) (37) (38) . Renal transplant recipients carrying the CYP3A4*22 allele required 30% less tacrolimus than those with the CYP3A4*1/*1 genotype (39) . Interestingly, the CYP3A4*22 genotype was mainly found in CYP3A5 non-expressers. CYP3A5 non-expressers recipients with CYP3A4*1/*22 genotype required a further 30% less tacrolimus than CYP3A5 non-expresser recipients with the CYP3A4*1/*1 genotype (39), suggesting that implementing personalised drug dosing based on the individuals genetic drug metabolism profile should be incorporated into clinical protocols. Whilst further work is required to realise drug dosing based on genetic variation, it could also play a role in predicting NODAT onset which occurs in 20% of patients on calcineurin inhibitors within the first six months after transplantation (41) . Calcineurin not only controls T cell signalling but in normal adult beta cells leads to NFAT activation, which promotes expression of numerous genes critical for beta cell function, proliferation and mass (42, 43) .
Mice with a beta cell specific calcineurin phosphatase regulatory subunit, calcineurin b1 (Cnb1) deletion develop age-dependent diabetes characterised by decreased beta cell proliferation and mass, reduced pancreatic insulin content and hypoinsulinemia (42) . Greater understanding of how variation in initial immunosuppressant dosing and metabolism could provide important insights into NODAT onset and have implications for pancreas transplant function in simultaneous pancreas-kidney transplants.
Immune Response Genes
The potential impact of immune system variation on rejection and long-term graft accommodation led to numerous immune genes being screened for a role in transplant outcome, with particular focus on screening other parts of the HLA region, complement, autoimmune genes and other immune response genes as detailed below:
Additional HLA associations
Due to the success of HLA matching in transplantation and the high density of immune response genes encoded within the HLA region, additional HLA genes have been screened including TNF-α (extensively reviewed in (44) ). Presence of strong linkage disequilibrium across the region, where variants within different HLA genes are inherited together in a nonrandom manner (8) , has hampered efforts to determine additional effects independent of HLA class I and class II matching, with work ongoing to tease these out. 
Complement
The complement cascade is a set of soluble and cell-bound components triggered by immune complexes (classical pathway), mannose-binding lectin and ficolins receptors (leptin pathway) or direct binding of C3b to the activated surface (alternative pathway) in response to pathogens, autoantibodies, apoptosis or ischemic cells (49, 50) . All three pathways lead to C3 activation, C3a and C5a release and formation of C5b-9 membrane attack complex resulting in cell disruption and lysis. Complement mediated injury can lead to hyper-acute and acute antibody mediated rejection and also plays a potential role in ischemic-reperfusion injury and cell mediated rejection (49) . The C4d component of the complement system has already been harnessed as a predictor of classical complement pathway activation and donor specific alloantibody production. Within the classical pathway, C3 production activates C4, causing cleavage of C4b from C4d (51). C4b is quickly degraded, whilst C4d remains attached to the cell membrane close to the site of antibody attachment providing a 'footprint' of antibodymediated tissue injury, with C4d staining incorporated into the BANFF grading scheme as a marker of acute humoral rejection (50) (51) (52) . The obvious role of complement in organ rejection has made it a target for genetic studies. Analysis of C3 in 622 kidney donor-recipient pairs for variants associated with fast (F) or slow (S) C3 production, demonstrated that C3 S/S recipients with a C3 F/F or C3 F/S donor had better long-term outcomes than those with a donor with C3 S/S genotype (53). These preliminary results suggest a potential opportunity to therapeutically target the complement pathways to improve transplant survival (49) , with further genetic screening of a role for variation in the complement system warranted.
Autoimmunity Variants
Variation in key regulators of T cell activation and function, including CTLA-4, PTPN22 and foxp3, has been associated with numerous autoimmune diseases (54) . Much work has been undertaken to look at autoimmune genes in transplant outcome, producing conflicting reports (55, 56) . Even meta-analysis of studies up to 2013 looking at selected variants within CTLA-4, CD86, CD28 and PDCD1 for a role in acute rejection only showed association of CD28 ivs3 +17 C allele with acute renal rejection (OR=1.74; 95% CI= 1.11-2.75, P=0.02) (55) . However, this meta-analysis, like most other studies, only screened selected variants within these gene regions, suggesting that until further screening of these autoimmune genes in larger, more statistically powerful transplantation datasets is undertaken it is impossible to rule out a role for these variants.
Cytokines and Other Immune Response Genes
Cytokines are produced by macrophages, T cells and B cells and play a key role in initiating and regulating the immune response. This has made these genes obvious potential triggers of acute and long-term rejection in transplantation, and after the HLA region are the most studied genes for a role in transplantation. Over the years various cytokines and other immune response genes (see Table 1 ), have been investigated, however a lack of consistent association of these genes with transplant survival has cast doubt over their potential role (as reviewed in (3, 7, 44,
57, 58)).
Incomplete screening of all common variation within these genes, combined with small datasets may, in part, explain the lack of consistent association (see Table 2 ). As the immune response is dynamic and varies significantly across the lifetime of the graft, this makes it inherently difficult to measure the impact of cytokines on transplant outcome. However, improvement in screening the genome and the use of larger datasets has enabled some evidence for a role of cytokines in transplant outcome to emerge. Meta-analysis of variants within transforming growth factor-beta 1 (TGF-β1), which is produced by all leukocytes and plays a key role in controlling inflammation (59, 60) , from five different studies showed some evidence for association of a TGF-β1 codon 10 polymorphism (OR=1.51, [95% CI=1.03-2.22]) with poor graft outcomes (57) . Interestingly, GWAS screening for new susceptibility loci for diabetic nephrology in type 1 diabetics revealed genome wide significance for AFF3, which play a role in TGF-β1 induced fibrosis in renal epithelial cells, providing further evidence for TGF-β1 pathways in renal dysfunction (61) . This suggests that whilst currently the role of cytokines in transplant outcomes remain uncertain, without further work we cannot rule out a role for these variants in transplant survival.
Fibrosis
Fibrosis is a key hallmark of graft rejection and is caused by dysregulated tissue repair and remodelling. Unlike normal wound healing, during fibrosis active scaring does not cease once the initial insult is contained, with connective tissue formation and wound contraction persisting, leading to disrupted tissue formation. Mechanisms behind fibrosis are unknown but have been proposed to be due to excess TGF-β1 and/or increased susceptibility of fibroblasts to persistent tissue re-modelling (62, 63) . TGF-β1 became an obvious target for genetic screening, with some evidence for a role in transplant loss found (see earlier). This opened the door for screening of other genes involved in fibrosis which may play a role in transplant survival.
Caveolin-1 (Cav-1) encodes part of caveolae, which form small invagination within the plasma membrane that act as specialized lipid rafts involved in signal transduction (64, 65) . Caveolae play a role within numerous tissue remodelling and fibrotic pathways, including TGF-β1 signalling and turn over, cell matrix interactions, fibroblast adhesion/migration, cell stretching and apoptosis (66) . Decreased Cav1 expression has been reported in affected tissues from several human fibrotic diseases including idiopathic pulmonary fibrosis, scleroderma and systemic sclerosis, with re-introduction of Cav1 function shown to rescue these phenotypes (66, 67) . Screening all common Cav1 variation in two independent UK kidney transplant cohorts showed presence of Cav1 rs4730751 single nucleotide polymorphism (SNP) AA genotype in kidney donors was associated with increased risk of allograft failure, HR=1.56-1.97 (67) . Importantly, the effect size of this variant is comparable with that of female donor gender and donor hypertension, both relevant clinical indicators of transplant success. Upon histological assessment of kidney graft failure, recipients who received grafts with the rs4730751 AA genotype had a predominant increase in interstitial fibrosis compared to donors with non-AA genotypes (67) . Variation in Cav1 has also been linked to decreased pancreas and lung transplant survival providing additional evidence for a role of fibrosis in long-term graft function (68-70). Interestingly, Cav1 knockout mice not only show impaired fibrosis but also exhibit lipid and metabolic disorders including insulin resistance (64, 71) . Caveolin-1 is an essential scaffolding protein required for correct folding of the insulin receptor, with incorrect insulin receptor formation leading to insulin resistance (64, 72) , suggesting Cav1 could contribute to reduced long-term graft function through other mechanisms in addition to fibrosis.
Whilst caveolin-1 is essential for caveolae formation, caveolin-2 is also involved in caveolae assembly in certain tissues (73) . Screening common Cav2 variation in 575 kidney donors and recipients revealed association of two SNPs in the recipients with graft function however these effects did not remain associated upon multivariate analysis (74) . Whilst no role for Cav2 was seen, screening other genes involved in caveolae formation/function could shed further light on the role of fibrosis in long-term graft function. In Apolipoprotein L1 (APOL1), which encodes a protein associated with plasma HDL cholesterol, two coding variants; a Serine to Glycine change at amino acid 342 (rs73885319) termed G1 and a six base pair deletion (rs71785313) termed G2, present in 30% of AfricanAmericans and only 0.3%-0.1% of Europeans, are strongly associated with hypertension attributed end-stage renal disease in African-Americans (76, 77) . When looking at 136 African Americans donor organ survival over 2 years, shorter graft survival rates were observed in recipients of donor kidneys with two APOL1 risk variants (HR=2.95, P=0.01) and in a fully adjusted model, two APOL1 risk alleles independently predicted graft failure (HR=3.84, P=0.008) (78). In African-Americans receiving deceased donors lacking two APOL1 risk variants, long-term survival rates were equivalent to those seen in non-African-American deceased kidney donor recipients in the US renal data systems between 1994-1998 (78).
Ethnic Differences in Transplant Outcome
APOL1 is expressed not only in the kidney but also in other organs including the liver, lung and placenta and is the only member of the apolipoprotein family that produces a soluble form (79) . This has led to questions over whether APOL1 variants contribute to transplant outcome by causing increased APOL1 in the kidneys leading to nephrotoxicity or through the soluble form of APOL1 causing altered binding/reabsorption of HDL (as reviewed in (79)).
Differences in APOL1 expression in normal kidneys compared to those from patients with HIV associated nephropathy (HIVAN) and focal segmental glomerulosclerosis (FSGS) has been found. In normal kidneys APOL1 expression was seen in podocytes, proximal tubules and arterial and arterior endothelial cells, whereas in HIVAN and FSGS APOL1 expression was reduced in the podocytes and tubules, with new expression seen in smooth muscles cells of the arterial walls (80) . When looking at APOL1 genotype in African-American kidney transplant recipients (those who had two APOL1 variants compared to those with one or no APOL1 variants) no differences in graft survival was seen over 5 years of follow up, adding further support that it is donor kidney APOL1 expression, not soluble APOL1, that contributes to decreased graft survival (81) . In vitro functional studies have also showed APOL1 risk variants cause podocyte swelling and reduced cellular viability at lower concentrations than wild-type APOL1 (82) . Whilst further work is required to confirm these observations, this work suggests that identifying ethnic specific pathways will provide greater insights into graft survival in different ethnicities.
Limitations of Candidate Gene Approach
Whilst progress has been made in identifying genetic predictors of kidney transplant function, for every gene identified, numerous others genes investigated showed no association or inconclusive results (3, 7) Several challenges have faced candidate gene studies which may explain this including sample size, incomplete gene screening, cohort differences and lack of multivariate analysis (see Table 2 ).
Combined with these issues, investigating genes based purely on their potential or perceived function, could miss novel gene pathways that could be targeted therapeutically to improve transplant outcome. Employing non-bias genome screening techniques is one way of overcoming this. Recent advances in genetic screening methodology, including microarrays, Genome Wide Association Studies (GWAS) and next generation sequencing, combined with greater collaboration between centres enabling establishment of larger kidney transplant datasets, with greater statistical power, are enabling many of these problems to be overcome.
With breakthroughs in these areas starting to emerge, the remainder of this review will focus on how these new advances are being utilised in transplantation.
Genome Screening in Renal Transplant
Non-bias monitoring of gene expression changes has been suggested as a way of identifying markers that could be used to predict graft rejection. Highly sensitive methods for quantifying gene transcripts, including real-time PCR, and large scale approaches such as microarrays have been employed to undertake transcriptional profiling of whole blood or graft biopsies. Whilst initially producing interesting results, microarray data in transplantation has suffered from lack of reproducibility across centres partially due to differences in cohort selection, treatment protocol and microarray technology (83) . To address this, meta-analysis was undertaken on 8 independent microarray datasets, 236 samples, using graft loss data from four commonly transplanted organs (kidney, liver, heart and lung) obtained at time of biopsies to identify gene transcripts common to acute rejection across multiple graft types (84) . Twelve gene transcripts, many of which were linked to NF-KB and STAT1 signalling pathways, were overexpressed during acute rejection across all tissues, termed the common rejection model (CRM). Six of these genes target drugs that modulate immunosuppression or immune/inflammatory pathways. Validation in 794 renal allograft biopsies from three independent datasets, confirmed 11 of these genes transcripts were crucial to the CRM. Over time both progressors and nonprogressors to transplant loss showed increased CRM scores but progressors CRM scores increased more rapidly (84) .
GWAS have also provided a new way of screening all common variation across the human genome (represented by >500,000 SNPs) for association with disease traits using high throughput chip genotyping technology. GWAS has revolutionised the search for genetic components to complex disease such as T1D and T2D, where within the space of a decade we have gone from a handful of known genes to >50 independent loci (85-88). Whilst GWAS has Interestingly, rs3811321 and rs6565887 also correlated with allograft failure (P=0.004 and P=0.03, respectively). Both SNPs came up in regions not previously associated with kidney transplant function, with rs3811321 located within the T cell receptor alpha which forms part of the T cell receptor complex and rs6565887 present in a non-coding intron of zinc finger protein 516, a member of C2H2-type zinc finger protein family located in nucleus cytoplasm, expressed in kidneys, spleen and lung (89) . Whilst further work is required to confirm these associations, this highlights the strength of GWAS to identify new genes and disease pathways that will inevitably provide novel insights into transplant function as more GWAS are reported over the next few years.
Insights from Related Diseases
Sharing of susceptibility loci between related diseases is well established. This suggests that screening of GWAS hits from related kidney traits, such as chronic kidney function, and genes involved in survival of other transplanted organs, on customised genotyping chips for a role in renal transplant survival would show whether long-term kidney graft survival is driven by any general transplant loss or kidney disease specific pathways and whether the same variants are driving these effects across different diseases.
Rare Variants
Whilst rare variants and copy number variation (CNVs) within the genome were originally believed to only contribute to monogenic forms of kidney disease, there is growing evidence that these variants may also impact upon complex disease. Advances in next generation sequencing technologies have enabled screening for rare variants and CNVs to become easier, with the genetic component to at least 160 different rare kidney diseases already identified (90) .
In the future, these technologies will enable us to determine if rare variants or CNVs also play a role in transplant outcome.
Translating Genetic Signals into Disease Pathways
One of the challenges this new influx of genetic data brings is how to determine the mechanisms driving these associations. Whilst association is assigned to a given gene, until fine mapping of the surrounding region, it is difficult to determine whether variation within that gene or a neighbouring gene region is truly driving the association detected. Even once fine mapping has been achieved, many of the variants driving association may be intronic or in gene deserts, requiring integration of information on gene expression, tissue specific expression, systems biology and animals models to determine how these variants impact upon transplant survival (91) . Several initiatives have been set up to aid this process including the ENCODE project which has published extensive information on regions of transcription, transcription factor association, chromatin structure and histone modification in the human genome and the European Renal cDNA bank which is collecting gene expression data from renal biopsies enabling determination of gene expression in renal tissue (92) (93) (94) (95) (96) . 
Epigenetic Changes
Temporal and reversible epigenetic alterations enable the body to silence or activate key genes in response to challenges encountered. Gene silencing via DNA methylation is one of the main epigenetic modifications within the body and whilst intrinsically difficult to monitor, some progress has been made accessing this.
Differences in hypermethylated gene regions between primary human fibroblasts from fibrotic kidneys compared to non-fibrotic kidneys were assessed by genome wide methylation screening (98) . Twelve genes including RASAL1, which has been associated with fibroblast activation and kidney fibrogenesis, were methylated in all 7 fibrotic fibroblast samples and non-methylated in all non-fibrotic fibroblasts, suggesting knockdown of these genes may be involved in onset of fibrosis (98) . Random inactivation of one X chromosome in females is also undertaken via methylation to enable dosage compensation with males who only have one copy of the X chromosome. This leads to random inactivation of either the paternal or maternal X chromosome (XCI), with females being a mosaic of the maternally and paternally derived X chromosome with an inactivation ratio of 50:50. In some cases one X chromosome is preferentially inactivated. A female with >80% of one X chromosome inactivated are known as skewed, and those with >90% of one X chromosome inactivated are known as extremely skewed. Investigating XCI levels in 212 white female recipients and 186 white donors, 8% of recipients with skewed XCI (2 of 25) developed biopsy proven acute rejection compared to 28.3% of non-skewed XCI recipients (53 of 187) HR=0.26, P=0.02 (99) . In donors, 66.6% with XCI skewing (4 of 6) (66.6%) developed acute rejection, compared with 20.5% of nonskewed donors without XCI skewing HR=3.30, P=0.03 (99) . XCI skewing in recipients has been suggested to lead to immunological senescence within the recipient resulting in less rejection and in donors XCI skewing could lead to stem cell senescence resulting in reduced graft survival, explaining the protective and predisposing of XCI skewing respectively (99) .
Taken together these studies show that whilst tricky to access, understanding epigenetic modifications will provide insights into long-term transplant function.
Relative Organ Age
Older donor kidneys have faster progression to tubular atrophy and are more susceptibility to chronic graft dysfunction and failure (100) (101) (102) . Kidney aging and decreased glomerular filtration rate becomes apparent after 40 years of age, however kidney function decline varies amongst individuals. Due to limited donor organ availability older organs are now being transplanted and, as such, markers that measure biological organ age could help optimize organ allocation. Telomeres, consisting of multiple copies of short nucleotide repeats at the end of all chromosomes, protect against chromosome deterioration. With each round of DNA replication, telomere length is reduced, which is believed to play a role in cell senescence and acts as a marker of organ 'age' (103, 104) . In primates, ischemia-reperfusion was associated with rapid decrease in telomere length, suggesting that changes in relative organ age caused by transplantation could impact upon long-term outcome (105) . To date, only limited studies have looked at telomere length and transplant outcome (106) to determine if relative graft 'age' impacts upon long-term function.
Recipient-Donor Genetic Interactions
With an increased number of genetic variants being associated with transplant survival and appreciation that both donor and recipient specific mechanisms could impact on graft outcome, one of the next challenges is to access how donor and recipient variants interact within a given individual and whether these pathways work synergistically or if one pathway plays a larger than others in long-term graft survival.
Conclusion
Advances in our ability to screen the genome, combined with greater understanding of how variants are linked to transplant outcome is providing new opportunities to learn more about the pathways behind graft survival and long-term function. The obvious next question is how do we use these new advances clinically to improve long-term transplant survival? Whilst it is important to bear in mind that clinical adaption of scientific discoveries is estimated to take up to 17 years (107), there are some more immediate ways in which genetic variation can impact upon long-term graft survival. Improved understanding of the disease pathways involved in transplant survival and loss can provide an opportunity to identify early on those at greater risk of graft failure and/or inform the selection of more appropriate donor organs for transplantation. Some genetic variants, such as those within CYP3A4 and CYP3A5 which affect immunosuppressant metabolism, have more immediate potential to be translated into clinical practice and debate is already underway over whether initial drug dosing based on genotype should be implemented into immunosuppressant regimes (35, 39).
Decreased costs and increased reproducibility of whole genome sequencing is opening the doors to enable personalised medicine to become a reality and information on genetic variation that can affect long-term transplant outcome will be vital to tailoring therapeutic regimes and treatment options for transplant recipients (108, 109) . In a time when drug design is becoming more expensive, the ability of genetics to identify new mechanisms involved in transplant loss could prove vital in identifying already approved drugs that could be re-purposed for use in transplant recipients to improve long-term graft function. Whilst it would be naive to say there are not challenges to face in both detecting genetic variation and translating the underlying mechanism (108, 109) , ongoing advances in our understanding of the genetic variation behind transplant organ survival will undoubtedly continue to translate into improvements in patient care with the ultimate goal of making kidney transplantation a lifelong treatment for renal failure. Binding of the T cell receptor (TCR) to HLA class II molecules presenting non-self antigens triggers TCR activation. This leads to calcium signalling, which intern activates calcineurin. Calcineurin activation leads to dephosphorylation of its substrates, including nuclear factor of activated T-cells (NFAT) complexes, which translocate to the nucleus and alter gene expression. Inhibition of calcineurin and downstream NFAT proteins by calcineurin inhibitors is key to inhibiting T cell activation, enabling graft accommodation. 
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